Primary prevention of cardiovascular disease in patients with systemic lupus erythematosus: case series and literature review

Lupus

Volumn 26, Issue 14, 2017, Pages 1463-1472

  Fasano, S ^a   Margiotta, D P ^b   Navarini, L ^b   Pierro, L ^a   Pantano, I ^a   Riccardi, A ^a   Afeltra, A ^b   Valentini, G ^a  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

aspirin; cardiovascular risk; hydroxychloroquine; statins; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PHOSPHOLIPID ANTIBODY;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL LABORATORY; CLINICAL OUTCOME; COHORT ANALYSIS; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LOW DRUG DOSE; MEDLINE; PREDICTOR VARIABLE; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; ADULT; COMPLICATION; FEMALE; IMMUNOLOGY; MALE; PROCEDURES; RISK FACTOR;

ADULT; ANTIBODIES, ANTIPHOSPHOLIPID; ASPIRIN; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PRIMARY PREVENTION; RISK FACTORS;

EID: 85032841139     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203317722847     Document Type: Review

References (50)

1. Jacobsen S, Petersen J, Ullman S, A multicentre study of 513 Danish patients with systemic lupus erythematosus. II. Disease mortality and clinical factors of prognostic value. Clin Rheumatol 1998; 17: 478–484.
2. Bartels CM, Buhr KA, Goldberg JW, Mortality and cardiovascular burden of systemic lupus erythematosus in a US population-based cohort. J Rheumatol 2014; 41: 680–687.
3. Urowitz MB, Bookman AA, Koehler BE, The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976; 60: 221–225.
4. Cervera R, Khamashta MA, Font J, Morbidity and mortality in systemic lupus erythematosus during a 10-year period: A comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore) 2003; 82: 299–308.
5. Doria A, Iaccarino L, Ghirardello A, Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med 2006; 119: 700–706.
6. Manzi S, Meilahn EN, Rairie JE, Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: Comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408–415.
7. Skamra C, Ramsey-Goldman R. Management of cardiovascular complications in systemic lupus erythematosus. Int J Clin Rheumatol 2010; 5: 75–100.
8. Iudici M, Fasano S, Gabriele Falcone L, Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study. Rheumatology (Oxford) 2016; 55: 1623–1630.
9. Fasano S, Pierro L, Pantano I, et al. Long-term hydroxychloroquine therapy and low-dose aspirin may have an additive effectiveness in the primary prevention of cardiovascular events in patients with systemic lupus erythematosus. J Rheumatol 2017; 44: 1032–1038
10. Atkins D, Best D, Briss PA, Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490–1490.
11. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725–1725.
12. Petri M, Orbai A-M, Alarcón GS, Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.
13. Bild DE, Bluemke DA, Burke GL, Multi-ethnic study of atherosclerosis: Objectives and design. Am J Epidemiol 2002; 156: 871–881.
14. Buyon JP, Petri MA, Kim MY, The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: A randomized trial. Ann Intern Med 2005; 142: 953–962.
15. Gladman D, Ginzler E, Goldsmith C, The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 1996; 39: 363–369.
16. Palmieri V, Migliaresi P, Orefice M, High prevalence of subclinical cardiovascular abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr Metab Cardiovasc Dis NMCD 2009; 19: 234–240.
17. The Multi-Ethnic Study of Atherosclerosis. Multi-ethnic study of atherosclerosis. MESA study events manual of operations. Bethesda, MD: National Heart, Lung, and Blood Institute, 2004
18. Hahn BH, McMahon MA, Wilkinson A, American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 2012; 64: 797–808.
19. Doria A, Shoenfeld Y, Wu R, Risk factors for subclinical atherosclerosis in a prospective cohort of patients with systemic lupus erythematosus. Ann Rheum Dis 2003; 62: 1071–1077.
20. Wahl DG, Bounameaux H, de Moerloose P, Prophylactic antithrombotic therapy for patients with systemic lupus erythematosus with or without antiphospholipid antibodies: Do the benefits outweigh the risks? A decision analysis. Arch Intern Med 2000; 160: 2042–2048.
21. Tektonidou MG, Laskari K, Panagiotakos DB, Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 2009; 61: 29–36.
22. Gustafsson JT, Simard JF, Gunnarsson I, Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus, a prospective cohort study. Arthritis Res Ther 2012; 14: R46–R46.
23. Bertoli AM, Vilá LM, Alarcón GS, Factors associated with arterial vascular events in PROFILE: A multiethnic lupus cohort. Lupus 2009; 18: 958–965.
24. Pons-Estel GJ, González LA, Zhang J, Predictors of cardiovascular damage in patients with systemic lupus erythematosus: Data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology (Oxford) 2009; 48: 817–822.
25. Fernández-Nebro A, Rúa-Figueroa Í, López-Longo FJ, Cardiovascular events in systemic lupus erythematosus: A nationwide study in Spain from the RELESSER registry. Medicine (Baltimore) 2015; 94: e1183–e1183.
26. Wallace DJ. Does hydroxychloroquine sulfate prevent clot formation in systemic lupus erythematosus? Arthritis Rheum 1987; 30: 1435–1436.
27. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577–583.
28. Jung H, Bobba R, Su J, The protective effect of antimalarial drugs on thrombovascular events in systemic lupus erythematosus. Arthritis Rheum 2010; 62: 863–868.
29. Petri M, Perez-Gutthann S, Spence D, Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93: 513–519.
30. Toloza SMA, Uribe AG, McGwin G, Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum 2004; 50: 3947–3957.
31. Ho KT, Ahn CW, Alarcón GS, Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXVIII. Factors predictive of thrombotic events. Rheumatology (Oxford) 2005; 44: 1303–1307.
32. Mok CC, Tang SSK, To CH, Incidence and risk factors of thromboembolism in systemic lupus erythematosus: A comparison of three ethnic groups. Arthritis Rheum 2005; 52: 2774–2782.
33. de Leeuw K, Freire B, Smit AJ, Traditional and non-traditional risk factors contribute to the development of accelerated atherosclerosis in patients with systemic lupus erythematosus. Lupus 2006; 15: 675–682.
34. Norby GE, Holme I, Fellström B, Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: A randomized placebo-controlled study. Arthritis Rheum 2009; 60: 1060–1064.
35. Yu H-H, Chen P-C, Yang Y-H, Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidaemia: A nationwide population-based cohort study. Atherosclerosis 2015; 243: 11–18.
36. Plazak W, Gryga K, Dziedzic H, Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: A prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther 2011; 13: R117–R117.
37. Mok CC, Wong CK, To CH, Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: A randomized, double-blind, placebo-controlled trial. Arthritis Care Res 2011; 63: 875–883.
38. Petri MA, Kiani AN, Post W, Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis 2011; 70: 760–765.
39. Ridker PM, Cook NR, Lee I-M, A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293–1304.
40. Achuthan S, Ahluwalia J, Shafiq N, Hydroxychloroquine’s efficacy as an antiplatelet agent study in healthy volunteers: A proof of concept study. J Cardiovasc Pharmacol Ther 2015; 20: 174–180.
41. Rand JH, Wu X-X, Quinn AS, Hydroxychloroquine directly reduces the binding of antiphospholipid antibody-beta2-glycoprotein I complexes to phospholipid bilayers. Blood 2008; 112: 1687–1695.
42. Virdis A, Tani C, Duranti E, Early treatment with hydroxychloroquine prevents the development of endothelial dysfunction in a murine model of systemic lupus erythematosus. Arthritis Res Ther 2015; 17: 277–286.
43. Petri M. Hydroxychloroquine use in the Baltimore lupus cohort: Effects on lipids, glucose and thrombosis. Lupus 1996; 5: S16–S22.
44. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. Circulation 2004; 109: III39–43.
45. Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 2006; 15: 577–583.
46. Goldberg RJ, Urowitz MB, Ibañez D, Risk factors for development of coronary artery disease in women with systemic lupus erythematosus. J Rheumatol 2009; 36: 2454–2461.
47. Burgos PI, McGwin G, Reveille JD, Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology (Oxford) 2010; 49: 1720–1725.
48. Zhang W, Aghdassi E, Reich HN, Glomerular filtration rate predicts arterial events in women with systemic lupus erythematosus. Rheumatol Oxf Engl 2011; 50: 799–805.
49. Yang L, Tao J, Tang X, Prevalence and correlation of conventional and lupus-specific risk factors for cardiovascular disease in Chinese systemic lupus erythematosus patients. J Eur Acad Dermatol Venereol JEADV 2012; 26: 95–101.
50. Kao AH, Lertratanakul A, Elliott JR, Relation of carotid intima-media thickness and plaque with incident cardiovascular events in women with systemic lupus erythematosus. Am J Cardiol 2013; 112: 1025–1032.